Taksande Amar, Prabhu Shakuntala, Venkatesh Sumitra
Department of Cardiology Unit, Bai Jerabai Wadia Hospital, Mumbai, India.
Cardiovasc Hematol Agents Med Chem. 2012 Mar 1;10(1):25-30. doi: 10.2174/187152512799201172.
Beta-thalassaemia major is a genetic blood disorder caused by the reduced synthesis of beta globin chain. The consequences of the resulting chronic anaemia are also common and include growth retardation, bone marrow expansion, extramedular hematopoiesis, splenomegaly, increased intestinal iron absorption, susceptibility to infections, and hypercoagulability. Transfusional iron overload can affect heart function by directly damaging tissue through iron deposition or via iron-mediated effects at other sites. Cardiac dysfunction is common in patients with thalassaemia and is the leading cause of mortality. The main cardiac abnormalities reported in patients with thalassaemia major (TM) and iron overload are left ventricular systolic and diastolic dysfunction, pulmonary hypertension, valvulopathies, arrhythmias and pericarditis. These cardiac abnormalities are a consequence of the general co-morbid conditions in thalassaemia but are closely related to concomitant endocrine deficiencies, hypercoagulability state and inflammatory milieu. Iron's toxicity within cells arises from its capacity to catalyse the production of reactive oxygen species that cause lipid peroxidation and organelle damage, which lead ultimately to cell death and fibrosis. With the introduction of new technologies such as cardiac magnetic resonance T2* , the early detection of cardiac iron overload and associated cardiac dysfunction is now possible, allowing time for reversal through iron chelation therapy.
重型β地中海贫血是一种遗传性血液疾病,由β珠蛋白链合成减少引起。由此导致的慢性贫血的后果也很常见,包括生长发育迟缓、骨髓扩张、髓外造血、脾肿大、肠道铁吸收增加、易感染和高凝状态。输血性铁过载可通过铁沉积直接损伤组织或通过在其他部位的铁介导作用影响心脏功能。心脏功能障碍在地中海贫血患者中很常见,是主要的死亡原因。重型地中海贫血(TM)和铁过载患者报告的主要心脏异常是左心室收缩和舒张功能障碍、肺动脉高压、瓣膜病、心律失常和心包炎。这些心脏异常是地中海贫血一般合并症的结果,但与伴随的内分泌缺陷、高凝状态和炎症环境密切相关。铁在细胞内的毒性源于其催化活性氧生成的能力,活性氧会导致脂质过氧化和细胞器损伤,最终导致细胞死亡和纤维化。随着心脏磁共振T2*等新技术的引入,现在可以早期检测心脏铁过载和相关的心脏功能障碍,从而有时间通过铁螯合疗法进行逆转。